Artivion, Inc. · NYSE:AORT
Artivion — Q1 2026 Earnings Presentation
20 slides from Artivion's earnings presentation, May 7, 2026
Slide 1: 1Q 2026 Earnings Presentation
1Q 2026 Earnings Presentation May 7, 2026 1 © 2026 Artivion, Inc.
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management’s beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect
Slide 3: Non-GAAP Financial Measures
NON-GAAP FINANCIAL MEASURES This presentation contains non-GAAP financial measures, including non-GAAP adjusted revenue, non-GAAP net income, EBITDA, adjusted EBITDA, non-GAAP general, administrative, and marketing expenses, and free cash flows. Investors should consider this non-GAAP information in
Slide 4: Table of Contents
TABLE OF CONTENTS Key Messages 5 Q1 2026 Financial Highlights 6 Product Revenue Growth 7 Geographic Revenue Growth 8 On-X vs Bioprosthetic Valve Data 9 AMDS PERSEVERE US IDE Study 10 Endospan’s NEXUS TRIOMPHE US IDE Study 11 ARTIZEN Pivotal IDE Study 12 Full Year 2026 Financial Guidance 13-14 Append
Slide 5: Q1 Key Messages
Q1 Key Messages Exercised Option to Acquire Endospan Following U.S. FDA PMA Approval of the NEXUS Aortic Arch System Utilized financing already in place; upfront acquisition purchase price of $135 million, net of previously extended loan $116.3M Acquisition expected to close in 2Q26 NEXUS U.S. comme
Slide 6: Q1 2026 Financial Highlights
Q1 2026 FINANCIAL HIGHLIGHTS GAAP Non-GAAP Q1 2026 Q1 2025 % Y/Y Δ Q1 2026 Q1 2025 % Y/Y Δ Revenue $116.3M $99.0M 17.5% Revenue $116.3M $104.3M 11.6% Gross Gross 64.9% 64.2% 70 bps 64.9% 64.2% 70 bps Margin Margin Diluted EPS $0.03 ($0.01) -- Diluted EPS $0.08 $0.06 -- Net income Adjusted $1.4M ($0.
Slide 7: Q1 2026 Year-Over-Year Revenue Growth: Product Portfolio
Q1 2026 Year-Over-Year Revenue Growth Product Portfolio Preservation Surgical Aortic Stent On-X Services Sealant Grafts GAAP Growth 23% 4% 20% 21% Constant Currency Growth 23% 0% 17% 10% 7 © 2026 Artivion, Inc.
Slide 8: Q1 2026 Year-Over-Year Revenue Growth Across Geographies
Q1 2026 Year-Over-Year Revenue Growth Across Geographies North Latin America America EMEA APAC GAAP Growth 23% -16% 19% 6% Constant Currency 23% -23% 5% 6% Growth 8 © 2026 Artivion, Inc.
Slide 9: On-X: High Growth, High Margin, with Market Upside
On-X: High Growth, High Margin, with Market Upside New Recently Published Data Across Three Leading Journals to Drive Potential $100 million Upside to Addressable U.S. Mechanical Heart Valve Market 5-year PAS Data Presented in April 20241 Demonstrated 87% Reduction in Major Bleeding Validated On
Slide 10: AMDS PERSEVERE US IDE Study Primary Endpoints
AMDSTM PERSEVERE US IDE Study Primary Endpoints Full IDE data demonstrates AMDS use significantly lowers 30-day Major Adverse Events (MAEs) compared to hemiarch control group ACUTE DEBAKEY TYPE I (ADTI) Through Hospital WITH MALPERFUSION Full 30-Day Discharge Data Data Hemiarch Reference Cohort Avg.
Slide 11: Endospan NEXUS TRIOMPHE US IDE Trial
Endospan NEXUS ® TRIOMPHE US IDE Trial 30-day data demonstrate 63% reduction in major adverse event (MAE) Presented at rate compared to the reference performance goal AATS 2026 30-DAY DATA 1 TRIOMPHE Performance p Value (n=54) Goal MAEs2 >=1 13.0% 35.0% p<0.001 Technical Failure 1.9% 30.0% p<0.001 3
Slide 12: ARTIZEN Pivotal IDE Study
ARTIZEN PIVOTAL IDE STUDY Prospective, Non-randomized, Non-blinded, Double-arm, Multicenter (US & EU ≈ 30 Sites) PRIMARY PATIENT GROUP 117 patients: Chronic dissection or Aneurysm Primary endpoint: Freedom from major adverse events (MAEs) within 1-year post-index procedure: all-cause mortality, new
Slide 13: Full Year 2026 Revenue Guidance
FULL YEAR 2026 REVENUE GUIDANCE GROWTH DRIVERS + Continued strength in existing products On-X and aortic stents $90.0M + Positive new data supporting the benefits of AMDS and On-X aortic valves $480M- Revenue* ($) $443.6M $496M + Continued adoption of AMDS following Y/Y cc. 13% 7-11% receipt of Huma
Slide 14: Revenue Growth and Operating Leverage to Drive Adjusted EBITDA Expansion
REVENUE GROWTH AND OPERATING LEVERAGE TO DRIVE ADJUSTED EBITDA EXPANSION FULL YEAR 2026 ADJUSTED EBITDA EXPECTATIONS DRIVERS Expect continued operating leverage to $90.0M be driven by gross margin expansion, global sales force and G&A infrastructure $100M- Adjusted EBITDA ($) $89.6M $107M Y/Y Growth
Slide 15: Appendix
Appendix 15 © 2026 Artivion, Inc.
Slide 16: GAAP to Non-GAAP Financial Reconciliations: Revenue
Q1 2026 GAAP to Non-GAAP Financial Reconciliations Revenue $ in thousands © 2026 Artivion, Inc. 16
Slide 17: GAAP to Non-GAAP Reconciliations: Diluted EPS
Q1 2026 GAAP to Non-GAAP Financial Reconciliations Reconciliation of diluted income (loss) per common share, GAAP to adjusted diluted income per common share, non-GAAP In thousands, except per share data © 2026 Artivion, Inc. 17
Slide 18: GAAP to Non-GAAP Reconciliations: Net Income and Adjusted EBITDA
Q1 2026 GAAP to Non-GAAP Financial Reconciliations Reconciliation of net income (loss), GAAP and EBITDA, non-GAAP to adjusted EBITDA, non-GAAP $ in thousands © 2026 Artivion, Inc. 18
Slide 19: GAAP to Non-GAAP Reconciliations: Free Cash Flows
Q1 2026 GAAP to Non-GAAP Financial Reconciliations Reconciliation of cash flows from operating activities, GAAP to free cash flows, non-GAAP $ in thousands © 2026 Artivion, Inc. 19
Slide 20: Thank You
Thank You © 2026 Artivion, Inc.